NWM
ALNY icon

Nova Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Nova Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-8
Closed -$2.65K – 594
2025
Q2 		$2.65K Sell
8
-9
-53% -$2.49K ﹤0.01% 518
2025
Q1 		$4.59K Buy
+17
New +$4.37K ﹤0.01% 385

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Nova Wealth Management's ALNY Position: Q3 2025 in Review

Nova Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2025, closing a stake of 8 shares — an estimated $2.65K sold.

Nova Wealth Management first reported a position in ALNY in Q1 2025 and held it in 2 quarters. The position peaked at $4.59K in Q1 2025. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Nova Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Nova Wealth Management sold 8 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $2.65K.
  • Nova Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Nova Wealth Management's Alnylam Pharmaceuticals position peaked at $4.59K in Q1 2025.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Nova Wealth Management's 13F filing for Q3 2025, filed 7 Oct 2025.